Cargando…
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423312/ https://www.ncbi.nlm.nih.gov/pubmed/30693373 http://dx.doi.org/10.1007/s00277-018-03592-9 |